Lilly spends $6.3 billion to acquire Centessa and accelerate its move into the sleep-disorder treatment market.
🧬 Eli Lilly has announced a deal to acquire Centessa for $38 per share in cash, with additional contingent payments tied to FDA milestones, bringing the total potential value of the transaction to $7.8 billion. The deal is expected to close in Q3 2026 and stands out as one of the most notable pharma M&A transactions of the year so far.
💤 The key attraction is cleminorexton, an OX2R agonist candidate that has already delivered encouraging Phase II data in narcolepsy and idiopathic hypersomnia. The acquisition gives Lilly immediate access to a highly regarded pipeline in sleep-wake disorders, a segment that still has meaningful room for new treatment options.
📈 Strategically, Lilly is using strong cash flow from its metabolic business to expand into neuroscience, reducing reliance on a single growth engine. If clinical development continues to progress smoothly, this deal could open up a new long-term revenue stream for Lilly over the next few years.